Jianxiong Jiang

List of Publications by Year in descending order

52 papers	2,636 citations	172457 29 h-index	197818 49 g-index
54 all docs	54 docs citations	54 times ranked	3317 citing authors

#	Article	IF	Citations
1	Lysine 63 Polyubiquitination of the Nerve Growth Factor Receptor TrkA Directs Internalization and Signaling. Molecular Cell, 2005, 20, 301-312.	9.7	236
2	Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside. Trends in Pharmacological Sciences, 2016, 37, 463-484.	8.7	160
3	Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends in Pharmacological Sciences, 2013, 34, 413-423.	8.7	146
4	Cyclooxygenaseâ€2 in epilepsy. Epilepsia, 2014, 55, 17-25.	5.1	146
5	Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3591-3596.	7.1	139
6	Cyclooxygenase-2 in glioblastoma multiforme. Drug Discovery Today, 2017, 22, 148-156.	6.4	103
7	Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3149-3154.	7.1	96
8	Subarachnoid blood acutely induces spreading depolarizations and early cortical infarction. Brain, 2017, 140, 2673-2690.	7.6	96
9	Role of Prostaglandin Receptor EP2 in the Regulations of Cancer Cell Proliferation, Invasion, and Inflammation. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 360-367.	2.5	94
10	EP2 Receptor Signaling Pathways Regulate Classical Activation of Microglia. Journal of Biological Chemistry, 2013, 288, 9293-9302.	3.4	87
11	SQSTM1/p62 Interacts with HDAC6 and Regulates Deacetylase Activity. PLoS ONE, 2013, 8, e76016.	2.5	87
12	Recent Advances in Anticancer Activities and Drug Delivery Systems of Tannins. Medicinal Research Reviews, 2017, 37, 665-701.	10.5	86
13	Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Neurobiology of Disease, 2015, 76, 126-136.	4.4	84
14	Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2307-2312.	7.1	79
15	Candidate Drug Targets for Prevention or Modification of Epilepsy. Annual Review of Pharmacology and Toxicology, 2015, 55, 229-247.	9.4	71
16	Prostaglandin E2 Signaling: Alternative Target for Glioblastoma?. Trends in Cancer, 2017, 3, 75-78.	7.4	64
17	Sequential combination therapy of ovarian cancer with cisplatin and Î³-secretase inhibitor MK-0752. Gynecologic Oncology, 2016, 140, 537-544.	1.4	54
18	Posttranslational Modifications and Receptor-Associated Proteins in AMPA Receptor Trafficking and Synaptic Plasticity. NeuroSignals, 2006, 15, 266-282.	0.9	53

#	Article	IF	Citations
19	Lead Optimization Studies of Cinnamic Amide EP2 Antagonists. Journal of Medicinal Chemistry, 2014, 57, 4173-4184.	6.4	49
20	Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype. Scientific Reports, 2017, 7, 9459.	3.3	45
21	Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury. Neuropharmacology, 2019, 149, 149-160.	4.1	42
22	Smallâ€molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenaseâ€associated malignant glioma growth. British Journal of Pharmacology, 2019, 176, 1680-1699.	5.4	42
23	EP2 Receptor Signaling Regulates Microglia Death. Molecular Pharmacology, 2015, 88, 161-170.	2.3	38
24	AMPA receptor trafficking and synaptic plasticity require SQSTM1/p62. Hippocampus, 2009, 19, 392-406.	1.9	37
25	Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer. Biotechnology Advances, 2015, 33, 224-241.	11.7	35
26	Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus. Expert Review of Neurotherapeutics, 2016, 16, 123-130.	2.8	35
27	G protein-coupled receptors in acquired epilepsy: Druggability and translatability. Progress in Neurobiology, 2019, 183, 101682.	5.7	34
28	Identification of a consensus site for TRAF6/p62 polyubiquitination. Biochemical and Biophysical Research Communications, 2008, 371, 521-524.	2.1	31
29	Development of second generation EP2 antagonists with high selectivity. European Journal of Medicinal Chemistry, 2014, 82, 521-535.	5.5	29
30	Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus. , 2020, 209, 107504.		29
31	COXâ€2/PGE₂ axis regulates hippocampal BDNF/TrkB signaling via EP2 receptor after prolonged seizures. Epilepsia Open, 2020, 5, 418-431.	2.4	27
32	Inverse Agonism of Cannabinoid Receptor Type 2 Confers Anti-inflammatory and Neuroprotective Effects Following Status Epileptics. Molecular Neurobiology, 2020, 57, 2830-2845.	4.0	26
33	Discovery and Characterization of Carbamothioylacrylamides As EP2 Selective Antagonists. ACS Medicinal Chemistry Letters, 2013, 4, 616-621.	2.8	25
34	aPKC Phosphorylation of HDAC6 Results in Increased Deacetylation Activity. PLoS ONE, 2015, 10, e0123191.	2.5	22
35	EP2 Antagonists (2011â€“2021): A Decadeâ€™s Journey from Discovery to Therapeutics. Journal of Medicinal Chemistry, 2021, 64, 11816-11836.	6.4	21
36	Prostaglandin E receptors as targets for ischemic stroke: Novel evidence and molecular mechanisms of efficacy. Pharmacological Research, 2021, 163, 105238.	7.1	20

#	Article	IF	Citations
37	Inhibiting the PGE₂ Receptor EP2 Mitigates Excitotoxicity and Ischemic Injury. ACS Pharmacology and Translational Science, 2020, 3, 635-643.	4.9	19
38	Discovery of 2-Piperidinyl Phenyl Benzamides and Trisubstituted Pyrimidines as Positive Allosteric Modulators of the Prostaglandin Receptor EP2. ACS Chemical Neuroscience, 2018, 9, 699-707.	3.5	18
39	Small molecules targeting cyclooxygenase/prostanoid cascade in experimental brain ischemia: Do they translate?. Medicinal Research Reviews, 2021, 41, 828-857.	10.5	15
40	Microglial TREM2 Mitigates Inflammatory Responses and Neuronal Apoptosis in Angiotensin II-Induced Hypertension in Middle-Aged Mice. Frontiers in Aging Neuroscience, 2021, 13, 716917.	3.4	15
41	Behavioral effects of SQSTM1/p62 overexpression in mice: Support for a mitochondrial role in depression and anxiety. Behavioural Brain Research, 2013, 248, 94-103.	2.2	14
42	PGE2 receptors in detrusor muscle: Drugging the undruggable for urgency. Biochemical Pharmacology, 2021, 184, 114363.	4.4	14
43	Inducible Prostaglandin E Synthase as a Pharmacological Target for Ischemic Stroke. Neurotherapeutics, 2022, 19, 366-385.	4.4	11
44	Assessment of the in vitro toxicity of calixarenes and a metal-seamed calixarene: a chemical pathway for clinical application. Supramolecular Chemistry, 2019, 31, 425-431.	1.2	10
45	Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation. Bioorganic and Medicinal Chemistry, 2022, 58, 116645.	3.0	9
46	Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects. Epilepsia, 2022, 63, 1003-1015.	5.1	8
47	Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma. Cell Reports, 2022, 39, 111000.	6.4	8
48	Distinct Cell-specific Roles of NOX2 and MyD88 in Epileptogenesis. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	8
49	Effect of TDP43-CTFs35 on Brain Endothelial Cell Functions in Cerebral Ischemic Injury. Molecular Neurobiology, 2022, 59, 4593-4611.	4.0	6
50	TRPC channels as emerging targets for seizure disorders. Trends in Pharmacological Sciences, 2022, , .	8.7	6
51	4R-cembranoid protects neuronal cells from oxygenâ€“glucose deprivation by modulating microglial cell activation. Brain Research Bulletin, 2022, 179, 74-82.	3.0	5
52	Abstract 3114: The role of prostaglandin signaling in human glioblastoma cell activities and growth in vitro and in vivo. , 2017, , .		0